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1 M 51·2 30·4 N Y 235 407·9 6·1 
2 M 37·8 48·1 N Y 175 291·2 25·2 
3 M 32·8 29·1 N Y 350 520·2 41·3 
4 M 20·1 41·9 N Y 238 343·0 25·9 
5 M 18·7 32·4 Y Y 135 400·3 31·9 
6 M 18·1 27·4 Y Y 348 353·9 39·8 
7 M 55·5 20·7 N N 397 575·1 19·4 
8 M 40·9 26·9 N N 480 349·6 12·7 
9 M 33·5 32·0 N N 292 397·7 49·1 
10 M 21·9 44·4 N Y 252 279·9 21·9 
11 M 27·6 26·3 N Y 320 550·8 82·9 
12 M 50·1 25·7 N Y 395 390·9 15·8 
13 M 42·9 25·0 N N 301 355·0 10·9 
14 M 35·7 24·6 N Y 337 573·9 70·3 
15 M 34·4 38·1 N Y 428 358·3 43·8 
16 M 29·2 27·8 N Y 284 379·9 61·1 
17 M 22·2 26·2 Y Y 339 484·2 25·9 
18 M 21·3 20·1 Y Y 253 285·4 28·3 
19 M 21·8 26·0 Y Y 274 483·5 34·9 
20 M 19·6 20·0 Y Y 395 363·0 70·7 
21 M 18·7 28·4 Y Y 208 451·2 40·1 
22 F 25·2 31·0 N Y 709 660·7 13·2 
23 F 21·8 34·4 N N 126 495·3 40·2 
24 F 20·9 36·9 Y Y 508 425·3 13·7 
25 F 29·9 37·7 N Y 579 499·1 9·5 
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26 F 29·7 26·8 Y N 295 454·4 118·9 
27 F 19·1 31·5 Y Y 480 298·2 31·0 
28 F 39·0 32·3 N Y 233 544·3 73·6 
29 F 29·1 32·8 Y Y 345 500·3 71·0 
30 F 27·6 33·9 Y Y 167 476·2 4·1 
31 F 22·5 21·7 Y Y 601 487·9 44·0 
32 F 22·3 27·2 N Y 317 429·0 27·6 
33 F 19·9 21·2 Y Y 477 600·0 43·7 
34 F 18·9 28·5 Y Y 764 547·3 98·5 
35 F 21·2 26·6 Y Y 245 510·9 30·5 
36 F 25·4 23·9 Y Y 384 471·0 12·0 
37 M 28·0 34·3 N Y 306 391·2 -1·4 
38 F 38·5 34·1 Y N 216 247·8 20·5 
39 F 29·5 31·5 N Y 202 567·1 58·9 
40 M 37·1 57·0 N N 414 381·1 12·2 
41 F 20·5 49·7 N Y 508 569·4 91·9 
42 M 21·4 20·6 Y Y 273 401·7 28·2 
43 M 51·1 29·4 N N 350 334·0 39·9 
44 M 19·4 24·7 Y Y 331 694·0 61·5 
45 M 22·9 25·6 Y N 356 386·7 46·9 
46 F 18·2 25·6 N N 239 603·1 106·9 
Y/N: yes/no. a M: male; F: female. b BMI: body mass index (kg/m2). c GH: current growth hormone treatment. d OAC: current use of oral estrogen or progesterone; 
testosterone: current use of testosterone. e 11-deoxycortisol (nmol/L) during multiple-dose metyrapone test. Cut-off for central adrenal insufficiency is <230 nmol/L.  


























47 M 22·4 28·3 N N 254 662 2·4 35·5 
48 M 37·8 28·0 N Y 306 734 1·9 28·1 
49 M 32·1 21·8 N Y 242 828 1·7 52·2 
50 M 30·7 24·3 N Y 153 552 1·4 90·5 
51 M 26·3 28·7 N N 165 687 1·7 44·4 
52 M 25·7 29·1 Y Y 119 532 1·9 63·4 
53 F 47·3 40·1 N Y 450 883 1·5 64·1 
54 F 31·8 34·6 Y N 133 778 2·1 61·5 
55 F 55·3 21·8 N N 502 717 1·9 21·2 
56 M 34·8 28·0 N Y 306 734 1·9 90·5 
Swedish patients 
57 M 20·0 21·2 N Y 177 632 2·6 NA 
58 M 22·0 44·4 N Y 181 822 1·6 NA 
59 M 25·0 24·2 N Y 194 502 1·7 NA 
60 M 27·0 27·5 N Y 265 703 1·9 NA 
61 F 31·0 36·5 N N 190 742 1·4 NA 
62 M 36·0 32·7 N Y 175 771 1·2 NA 
French patients 
63 M 18·0 47·8 N NA 229 665 1·6 NA 
64 M 20·0 49·7 N NA 235 563 2·0 NA 























66 F 29·0 32·0 N NA 229 944 1·5 NA 
67 F 24·0 31·8 N NA 102 712 1·6 NA 
68 F 28·0 58·2 N NA 166 759 1·7 NA 
69 F 38·0 27·3 N NA 384 1021 0·9 NA 
70 F 23·0 20·3 N NA 116 789 2·2 NA 
71 F 19·0 43·6 N NA 132 601 1·4 NA 
72 F 18·0 24·0 N NA 240 869 0·6 NA 
British patients 
73 F 18·3 33·8 N Y 327 817 2·1 NA 
74 M 30·9 24·1 N N 242 603 1·1 NA 
75 F 19·3 26·9 Y Y 166 535 1·4 NA 
76 F 19·4 29·9 N N 179 510 1·0 NA 
77 F 20·6 30·7 N Y 148 455 1·7 NA 
78 M 23·7 34·9 Y N 296 538 1·7 NA 
79 M 19·3 24·8 N N 93 502 1·5 NA 
80 F 19·2 35·2 N Y 545 971 1·8 NA 
81 M 26·1 62·0 N N 119 467 1·5 NA 
82 M 24·7 57·2 N N 120 496 1·4 NA 
Y/N: yes/no. NA: Not available. a M: male; F: female. b BMI: body mass index (kg/m2). c GH: current growth hormone treatment. d OAC: current use of oral estrogen or 
progesterone; testosterone: current use of testosterone. e Peak cortisol (nmol/L) level during insulin tolerance test. Cut-off for central adrenal insufficiency is <500 nmol/L 




a LDSST: Low-dose short synacthen test. b HDSST: High-dose short synacthen test. c MTP: Metyrapone test. d ITT: Insulin tolerance test. 













Synthetic ACTH administration induces release of cortisol 





 Adequate for the diagnosis of primary adrenal insufficiency, but lack of 
consensus about use for the diagnosis of central adrenal insufficiency. 
   MTPc 2 Metyrapone decreases cortisol production by inhibiting the 
11ß-hydroxylase steroid enzyme. This stimulates ACTH 
production, leading to increased 11-deoxycortisol levels.  
88-100 88-100  Risk of acute adrenal insufficiency precipitated by metyrapone ingestion 
 Should be conducted on an inpatient basis. 
   ITTd Insulin induces hypoglycaemia, which causes a release in 
ACTH and growth hormone (GH), leading to increased levels 
of cortisol.  
Golden standard Golden standard  Risks associated with hypoglycaemia 
 Intravenous access at two different sites needed, which is impossible in 
many patients with PWS  
 Labour intensive, time consuming, unpleasant for patient 
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Figure S1. Relation between cortisol level (nmol/L) at baseline and increase in ACTH (pmol/L) during multiple-
dose metyrapone test in patients with Prader-Willi syndrome 
 
Relationship between baseline cortisol (nmol/L) and increase in ACTH (pmol/L) in Dutch patients with Prader-





















Figure S2. ACTH levels (pmol/L) in Dutch patients with Prader-Willi syndrome who underwent the multiple-




Spaghetti plot of the ACTH levels (pmol/L) in patients with Prader-Willi syndrome who underwent the multiple-
dose metyrapone test (MTP; black line) or insulin tolerance test (ITT; blue line). For MTP test, n = 46. For ITT, 
n = 26. Median (range) ACTH level before and after metyrapone administration (MTP) were 3·5 (1·3 – 16·2) 
pmol/L and 37·7 (2·8 – 132·0) pmol/L. Median (range) ACTH level before and after insulin administration 
(ITT) were 3·3 (1·1 – 6·2) pmol/L and 61·2 (23·8 – 93·5) pmol/L. The grey arrow represents the ACTH cut-off 
value of 33 pmol/L, used for interpretation of the MTP in the Dutch pediatric study.4 This would classify 21 
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